Extended Data Fig. 8: Changes in biomarkers of liver fibrosis after 12 weeks of treatment with licogliflozin. | Nature Medicine

Extended Data Fig. 8: Changes in biomarkers of liver fibrosis after 12 weeks of treatment with licogliflozin.

From: Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study

Extended Data Fig. 8: Changes in biomarkers of liver fibrosis after 12 weeks of treatment with licogliflozin.

Data presented in subfigures (a–c) as geometric mean ratio to baseline, and in subfigure d, as mean change from baseline. a, PRO-C3; b, APRI; c, FIB4; d, NAFLD fibrosis score. Baseline is defined as the last available measurement prior to the first dose. P values based on two-sided ANCOVA test. N for placebo, licogliflozin 30 mg, and 150 mg are 21, 43, and 37 (APRI, FIB4, NAFLD fibrosis score) 20, 42, and 34 (Pro-C3). Error bars represent s.e.

Back to article page